|
Dec 28, 2009
|
FIFTEEN PERCENT OF ADXS11-001 TREATED CERVIX CANCER PATIENTS STILL ALIVE THREE YEARS AFTER INITIAL DOSING
|
|
Dec 17, 2009
|
ADVAXIS APPROVED TO SELL APPROXIMATELY $300,000 WORTH OF NET OPERATING TAX LOSSES, RESEARCH TAX CREDITS
|
|
Dec 15, 2009
|
ADVAXIS ANNOUNCES PHASE II TRIAL COLLABORATION WITH THE NATIONAL CANCER INSTITUTE
|
|
Nov 17, 2009
|
ADVAXIS TO PRESENT AT THE LD MICRO GROWTH CONFERENCE
|
|
Oct 29, 2009
|
BIO Conference Presentation
|
|
Oct 15, 2009
|
Advaxis Chief Science Officer To Present Benefits of Using Live, Listeria As A Vaccine
|
|
Oct 14, 2009
|
Advaxis Added to Stonegate's Equity Universe
|
|
Oct 8, 2009
|
Advaxis Live Listeria Vaccine Induces Epitope Spreading
|
|
Oct 1, 2009
|
Updated Advaxis Phase I Survival Data Indicates Long-Term Immune Protection
|
|
Sep 24, 2009
|
Advaxis Secures $5.0 Million investment
|
|
Sep 24, 2009
|
Advaxis Cures Late Form 10-Q Filing
|
|
Sep 23, 2009
|
CORRECTING and REPLACING Advaxis Granted New Compositions and Methods Patent
|
|
Aug 20, 2009
|
The U.S. National Institute of Health Awards Advaxis $210,000 for the Development of a Dual Antigen Vaccine
|
|
Aug 15, 2009
|
Advaxis to Collaborate with City of Hope
|
|
Jun 23, 2009
|
Advaxis Engages the Numoda Corporation to Oversee Phase II Clinical Trials of ADXS11-001
|
|
Jun 18, 2009
|
Advaxis Completes Debt Financing
|
|
Jun 12, 2009
|
Advaxis Receives US Patent and Trademark Office Approval on Act-A Protein Patent-Pending Rights
|
|
Jun 2, 2009
|
Advaxis Receives FDA Response to Orphan Drug Filing
|
|
Jun 1, 2009
|
Advaxis Develops Innovative Approach in Cancer Mechanism Targeting
|
|
May 27, 2009
|
Advaxis CEO Thomas A. Moore Interviewed
|
|
May 26, 2009
|
Advaxis Receives US Patent and Trademark Office Approval on Act-A Protein Patent-Pending Rights
|
|
May 20, 2009
|
Advaxis Applies for $2.0 Million U.S. Bio-Defense Grant
|
|
May 11, 2009
|
Advaxis Scientific Founder Published in Prestigious Peer-Reviewed Journal of Immunology
|
|
May 6, 2009
|
Advaxis Explores New Drug Licensing Opportunities
|
|
May 4, 2009
|
Advaxis Applies for Approximately $5.0 Million in Grants in Response to U.S. Department of Defense Solicitation
|
|
Apr 29, 2009
|
Advaxis' Phase 1 Clinical Cervix Cancer Study Accepted for Publication in Leading Peer-Reviewed Science Journal Vaccine
|
|
Apr 27, 2009
|
Advaxis Applies for Approximately $1.0 Million Worth of Grants from the National Institute of Health
|
|
Apr 17, 2009
|
Advaxis in Drug Licensing Discussions for its Flagship Vaccine Construct, ADXS1-001
|
|
Mar 29, 2009
|
Advaxis Updates Phase I Trial Survival Data: 23% of Patients Still Surviving after 2+ Years
|
|
Mar 10, 2009
|
Advaxis Submits ADXS11-001 for Orphan Drug Designation
|
|
Feb 11, 2009
|
New Intellectual Property Patent For Advaxis Issued
|
|
Jan 14, 2009
|
Advaxis Prevails In European Patent Court
|
